Retatrutide: the triple-agonist obesity drug and its record 24% weight loss (2026)

The short version

Retatrutide (Eli Lilly's LY3437943) is an investigational once-weekly injectable that activates three receptors — GIP, GLP-1, and glucagon. In its phase 2 trial it produced about 24% average weight loss at 48 weeks, the highest figure published for any obesity drug so far. It is not approved and cannot be prescribed. This page explains the real evidence, how it stacks up against the drugs you can actually get, and what to do while phase 3 runs.

What makes it a 'triple agonist'

The current obesity drugs work by mimicking gut and pancreatic hormones that control appetite, blood sugar, and how fast the stomach empties. The generations are defined by how many receptors they hit at once. Semaglutide (Ozempic, Wegovy) mimics one hormone: GLP-1. Tirzepatide (Mounjaro, Zepbound) mimics two: GIP and GLP-1. Retatrutide mimics three, adding a glucagon-receptor agonist to the GIP and GLP-1 pair [1].

Each added receptor is a bet that a new mechanism will stack more benefit on top of the last. The two-receptor tirzepatide out-lost the one-receptor semaglutide in a head-to-head trial (SURMOUNT-5) [4]. Retatrutide's phase 2 result — larger still — is the early signal that a third receptor keeps adding, though it has not yet been proven against tirzepatide directly.

The three hormones, and what each one does

GLP-1 (glucagon-like peptide-1) is the workhorse of the current drugs. It amplifies insulin release after meals, slows gastric emptying, and acts on the brain's appetite centers to reduce hunger and food intake. Every approved drug in this class leans on it [1].

GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone. Adding GIP activity, as tirzepatide does, appears to improve the insulin response and may also blunt the nausea of GLP-1 alone, allowing more appetite suppression to be tolerated [1].

Glucagon is the new and counterintuitive piece. On its own it raises blood sugar, but glucagon-receptor activity also increases resting energy expenditure and pushes the liver to burn stored fat. In retatrutide, the GLP-1 and GIP arms keep blood sugar in check while the glucagon arm adds a calorie-burning effect that appetite suppression alone can't provide. That is the leading explanation for why three receptors produced more weight loss than two [1].

What the phase 2 trial showed

The phase 2 trial enrolled 338 adults with obesity (or overweight plus a weight-related condition) and randomly assigned them to retatrutide at weekly doses from 1 mg to 12 mg, or to placebo, for 48 weeks. The design tested several dose-escalation schedules to find the best balance of effect and tolerability [1].

At 48 weeks, average body-weight reduction rose steadily with dose: 8.7% at 1 mg, 17.1% at 4 mg, 22.8% at 8 mg, and 24.2% at 12 mg, versus just 2.1% on placebo. At the 12 mg dose, 100% of participants lost at least 5% of their body weight, 93% lost at least 10%, and 83% lost at least 15% [1].

Two details drove the excitement. First, 24.2% is the largest average weight loss published for any obesity medication to date. Second, the weight-loss curve in the higher-dose groups had not clearly flattened by week 48 — meaning participants might have kept losing with more time, something the longer phase 3 trials will test [1].

How retatrutide compares with the drugs you can get today

Put the pivotal-trial figures side by side and the generational trend is clear, with the caveat that these come from separate trials in different populations — not a single head-to-head. Semaglutide 2.4 mg (Wegovy) produced about 14.9% mean weight loss at 68 weeks in STEP-1 [3]. Tirzepatide 15 mg (Zepbound) reached about 20.9% at 72 weeks in SURMOUNT-1 [2]. In the one direct comparison of the two approved drugs, SURMOUNT-5, tirzepatide beat semaglutide (about 20% vs 14%) [4]. Retatrutide 12 mg reached 24.2% at 48 weeks in phase 2 [1].

So the honest read is: retatrutide's early number is the highest yet, and it got there in less time (48 weeks vs 68-72), but a cross-trial number is a hypothesis, not a verdict. It has to be confirmed in phase 3, ideally against tirzepatide, before anyone can say it is truly more effective. And efficacy is only half the story — tirzepatide and semaglutide are approved, available, and backed by real-world safety data, while retatrutide is years of trials away from a pharmacy shelf.

Safety signals so far

The most common side effects were gastrointestinal — nausea, diarrhea, vomiting, constipation — dose-related and mostly mild to moderate, the same profile as the approved GLP-1 drugs. Starting at a lower dose (2 mg rather than 4 mg) partially reduced them, which is why phase 3 uses gradual escalation [1].

The signal unique to retatrutide is a dose-dependent increase in heart rate that peaked around 24 weeks and then declined [1]. This is linked to the glucagon-receptor activity and is exactly the kind of effect a 338-person, 48-week phase 2 study can flag but not fully characterize. Whether it matters for cardiovascular safety over years is one of the central questions the phase 3 program must answer. This uncertainty is a concrete reason to wait for the full data rather than chase the drug early.

The TRIUMPH phase 3 program: what's being tested

Retatrutide's phase 3 development is a multi-trial program (branded TRIUMPH) that goes well beyond weight. It includes large obesity trials, a type 2 diabetes program, and studies in conditions where weight and metabolism play a central role, such as knee osteoarthritis and cardiometabolic disease. The glucagon mechanism also makes it a candidate for fatty liver disease, where mobilizing liver fat is the therapeutic goal [1].

Phase 3 exists to answer the questions phase 2 can't: does the weight loss hold up in thousands of patients over one to two years, what are the rare but serious risks, and does the heart-rate signal translate into any cardiovascular harm or benefit? Until those read out and the FDA reviews them, every claim about retatrutide is provisional.

Cost, access, and why 'retatrutide for sale' online is a red flag

There is no legal retatrutide supply. Because it is unapproved, no pharmacy — compounding or otherwise — can lawfully dispense it, and there is no manufacturer price because it is not on the market. Any website, peptide vendor, or clinic offering 'retatrutide' is selling an unregulated product outside the FDA system [1].

This is worth stating plainly because the gray market is real. Unlike the compounded semaglutide and tirzepatide that circulated during official FDA-declared shortages, there is no shortage pathway for a molecule that was never approved. Gray-market vials can't be verified for identity, dose, purity, or sterility; an unsterile injectable is an infection risk; and a mislabeled dose of a potent triple agonist is a real hazard. When retatrutide does reach the market, it will come with a brand name, an FDA label, and a prescription — not a checkout cart on a supplement site.

Who might it be for, and what to do now

If retatrutide is eventually approved, the likely candidates are the same people who qualify for today's obesity drugs — adults with obesity, or overweight plus a weight-related condition — especially those who want or need larger weight loss, or who have coexisting metabolic problems the triple mechanism might address. None of that is settled until phase 3 and FDA review are complete [1].

For now, the evidence-based move is not to wait. If you qualify for weight-loss medication, semaglutide (Wegovy) and tirzepatide (Zepbound) are approved, available, and produce clinically major weight loss under a clinician's care. Starting an approved drug now, and following the pipeline, beats delaying treatment for a drug that may be years away — and it certainly beats buying an unregulated version. Retatrutide is worth watching, not chasing.